RP103

DRUG4 trials

Sponsors

Amgen, University Hospital, Angers

Conditions

CystinosisHuntington's Disease

Phase 1

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

CompletedNCT00872729

AmgenCystinosis

Start: 2009-05-31End: 2009-10-31Updated: 2024-12-19

Phase 2

Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

University Hospital, AngersHuntington's Disease

Start: 2010-10-31Updated: 2014-04-02

Phase 3

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

CompletedNCT01733316

AmgenCystinosis

Start: 2013-01-31End: 2017-07-10Updated: 2024-12-27

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

CompletedNCT01744782

AmgenCystinosis

Start: 2012-12-20End: 2016-12-13Updated: 2024-12-27